This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Timothy Weeden
Vice President- Head of Platform Discovery at Dyne Therapeutics
Speaker

Profile

Tim Weeden is a leading researcher in the field of oligonucleotide therapeutics, with over 20 years of experience in the discovery and development of small molecules, peptides, and antibody therapeutics across areas of immunology and rare disease. He initiated research efforts focused on the design of the FORCETM platform at Dyne Therapeutics and leads the broader implementation of pipeline and second-generation products. Tim has over 50 issued patents and authored a number of peer-reviewed articles published in leading scientific journals. Tim holds a B.S. degree in Biochemistry from Bridgewater State University.

Agenda Sessions

  • Clinical Translation of the FORCE™ Platform for Targeted Oligonucleotide Delivery

    3:00pm